To Bleed or Not to Bleed: That is the Question. The Side Effects of Apixaban

Author(s): Marco Matteo Ciccone*, Annapaola Zito, Fiorella Devito, Maria Maiello, Pasquale Palmiero

Journal Name: Current Drug Targets

Volume 19 , Issue 6 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Apixaban is a new oral anticoagulant (NOACs: Novel Oral Anticoagulant), like dabigatran, rivaroxaban, and edoxaban. All of them are prescribed to patients with non valvular atrial fibrillation or venous thromboembolism, to replace warfarin, because of the lower probability of bleeding, however they can cause bleeding by themselves. Bleeding is an adverse event in patients taking anticoagulants. It is associated with a significant increase of morbidity and risk of death. However, these drugs should be used only for the time when anticoagulation is strictly required, especially when used for preventing deep vein thrombosis. Prolonged use increases the risk of bleeding. In the ARISTOTLE Trial Apixaban, compared with warfarin, was associated with a lower rate of intracranial hemorrhages and less adverse consequences following extracranial hemorrhage. Many physicians still have limited experience with new oral anticoagulants and about bleeding risk managment. We reviewed the available literature on extracranial and intracranial bleeding concerning apixaban.

Keywords: Apixaban, extracranial, intracranial bleeding, anticoagulant, thrombosis, artial fibrillation.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [581 - 584]
Pages: 4
DOI: 10.2174/1389450116666151001113932
Price: $65

Article Metrics

PDF: 49
PRC: 1